Bosutinib
CAS 380843-75-4
Bosutinib (CAS 380843-75-4) is a pharmaceutical compound with 80 bioactivity targets and 877 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
204
SOURCE
DrugCentral
Adverse signals
877
SOURCE
IUPHAR/BPS
PubMed IDs
4
SOURCE
DrugCentral
055904D152D6
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Bosutinib
CAS Number
380843-75-4
UNII
5018V4AEZ0
InChIKey
UBPYILGKFZZVDX-UHFFFAOYSA-N
ChEMBL ID
CHEMBL288441
DrugCentral Struct ID
4359
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
Synonyms and normalized names
BOSUTINIB MONOHYDRATEBosulif
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 5.92 | - | Homo sapiens |
| Macrophage-stimulating protein receptor Kinase |
Kd | 5.2 | - | Homo sapiens |
| ATP-binding cassette sub-family G member 2 Transporter |
IC50 | 5.7 | - | Homo sapiens |
| Platelet-derived growth factor receptor beta Kinase |
Kd | 6.7 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 10.54 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 7.14 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 7.74 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 9 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 9.23 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 8.4 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 7.96 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 7.74 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 6 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 5.42 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 6.42 | - | Homo sapiens |
| Platelet-derived growth factor receptor alpha Kinase |
Kd | 5.29 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-2 Kinase |
Kd | 5.6 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-3 Kinase |
Kd | 5.92 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase |
Kd | 5.89 | - | Homo sapiens |
| Myosin light chain kinase, smooth muscle Kinase |
Kd | 6.31 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 6.06 | - | Homo sapiens |
| Focal adhesion kinase 1 Kinase |
Kd | 6.24 | - | Homo sapiens |
| Tyrosine-protein kinase HCK Kinase |
Kd | 8.47 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK1 Kinase |
Kd | 5.74 | - | Homo sapiens |
| Receptor tyrosine-protein kinase erbB-4 Kinase |
Kd | 7.59 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 5.51 | - | Homo sapiens |
| Protein kinase C delta type Kinase |
Kd | 5.8 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 5.96 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 6.44 | - | Homo sapiens |
| Tyrosine-protein kinase SYK Kinase |
Kd | 6.54 | - | Homo sapiens |
| Tyrosine-protein kinase CSK Kinase |
Kd | 7.49 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 5.41 | - | Homo sapiens |
| Ephrin type-A receptor 8 Kinase |
Kd | 8.05 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase |
Kd | 5.44 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 5.64 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 5.66 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 8.38 | - | Homo sapiens |
| Cytoplasmic tyrosine-protein kinase BMX Kinase |
Kd | 6.7 | - | Homo sapiens |
| Serine/threonine-protein kinase Nek2 Kinase |
Kd | 5.8 | - | Homo sapiens |
| Ribosomal protein S6 kinase alpha-2 Kinase |
Kd | 5.49 | - | Homo sapiens |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase |
Kd | 5.41 | - | Homo sapiens |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase |
Kd | 6.47 | - | Homo sapiens |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase |
Kd | 5.35 | - | Homo sapiens |
| Serine/threonine-protein kinase 10 Kinase |
Kd | 8.15 | - | Homo sapiens |
| Tyrosine-protein kinase Fer Kinase |
Kd | 6.44 | - | Homo sapiens |
| Protein kinase C epsilon type Kinase |
Kd | 5.62 | - | Homo sapiens |
| Abelson tyrosine-protein kinase 2 Kinase |
Kd | 8.82 | - | Homo sapiens |
| Ephrin type-A receptor 5 Kinase |
Kd | 7.57 | - | Homo sapiens |
| Ephrin type-A receptor 4 Kinase |
Kd | 7.74 | - | Homo sapiens |
| Serine/threonine-protein kinase N1 Kinase |
Kd | 5.54 | - | Homo sapiens |
SOURCE
DrugCentral
41 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Diarrhoea | 1152 | 1399.901 | 10012735 |
| Neoplasm progression | 215 | 502.319 | 10061309 |
| Pleural effusion | 276 | 438.577 | 10035598 |
| Cytogenetic analysis abnormal | 65 | 303.421 | 10059887 |
| Nausea | 552 | 297.753 | 10028813 |
| Drug resistance | 102 | 172.241 | 10059866 |
| Philadelphia chromosome positive | 30 | 139.197 | 10034877 |
| Drug intolerance | 209 | 133.665 | 10061822 |
| Rash | 305 | 124.228 | 10037844 |
| Second primary malignancy | 56 | 120.807 | 10039801 |
| Vomiting | 298 | 112.889 | 10047700 |
| Blast crisis in myelogenous leukaemia | 25 | 100.922 | 10050282 |
| Fatigue | 381 | 97.312 | 10016256 |
| Cytopenia | 46 | 73.639 | 10066274 |
| Fluid retention | 68 | 65.514 | 10016807 |
| Abdominal pain upper | 123 | 60.426 | 10000087 |
| Abdominal pain | 164 | 58.95 | 10000081 |
| Death | 228 | 52.015 | 10011906 |
| Pulmonary hypertension | 47 | 46.536 | 10037400 |
| Pericardial effusion | 44 | 42.825 | 10034474 |
| Pulmonary oedema | 59 | 41.934 | 10037423 |
| Peripheral arterial occlusive disease | 22 | 40.827 | 10062585 |
| Acquired gene mutation | 14 | 38.459 | 10069754 |
| Bone pain | 48 | 37.049 | 10006002 |
| Myopathy toxic | 11 | 34.796 | 10028648 |
| Illness | 42 | 33.505 | 10080284 |
| Clonal evolution | 7 | 31.242 | 10065163 |
| Cardiac failure | 72 | 31.054 | 10007554 |
| Drug ineffective | 107 | 29.912 | 10013709 |
| Liver function test increased | 34 | 28.906 | 10077692 |
| Therapy interrupted | 32 | 28.285 | 10066377 |
| Therapy cessation | 33 | 28.273 | 10065154 |
| Rheumatoid arthritis | 4 | 28.104 | 10039073 |
| Muscle disorder | 15 | 26.408 | 10028300 |
| Pancreatitis | 44 | 25.885 | 10033645 |
| White blood cell count increased | 44 | 25.35 | 10047943 |
| Renal disorder | 35 | 25.12 | 10038428 |
| Haematotoxicity | 21 | 23.772 | 10061188 |
| Chronic myeloid leukaemia transformation | 6 | 23.416 | 10068232 |
| Chylothorax | 8 | 23.28 | 10051228 |
| Disease progression | 79 | 23.027 | 10061818 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
16 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| ABL proto-oncogene 1, non-receptor tyrosine kinase ABL1 |
Inhibition | 9.0 pIC50 | 12543790 |
| FYN proto-oncogene, Src family tyrosine kinase FYN |
Inhibition | 8.739999771118164 pIC50 | 19039322 |
| LYN proto-oncogene, Src family tyrosine kinase LYN |
Inhibition | 8.100000381469727 pIC50 | 19039322 |
| SIK family kinase 3 SIK3 |
Inhibition | 7.739999771118164 pIC50 | 25351958 |
| SRC proto-oncogene, non-receptor tyrosine kinase SRC |
Inhibition | 9.0 pIC50 | 17721511 |
| TXK tyrosine kinase TXK |
Inhibition | 9.520000457763672 pIC50 | 19039322 |
| calcium/calmodulin dependent protein kinase ID CAMK1D |
Inhibition | 7.039999961853027 pIC50 | 19039322 |
| calcium/calmodulin-dependent protein kinase II gamma subunit CAMK2G |
Inhibition | 6.739999771118164 pIC50 | 19039322 |
| fyn related Src family tyrosine kinase FRK |
Inhibition | 8.65999984741211 pIC50 | 19039322 |
| mitogen-activated protein kinase kinase kinase kinase 5 MAP4K5 |
Inhibition | 9.520000457763672 pIC50 | 19039322 |
| salt inducible kinase 1 SIK1 |
Inhibition | 8.520000457763672 pIC50 | 25351958 |
| salt inducible kinase 2 SIK2 |
Inhibition | 8.520000457763672 pIC50 | 25351958 |
| serine/threonine kinase 10 STK10 |
Inhibitor | 7.28000020980835 pIC50 | 19039322 |
| serine/threonine kinase 24 STK24 |
Inhibition | 8.40999984741211 pIC50 | 19039322 |
| serine/threonine kinase 4 STK4 |
Inhibition | 6.71999979019165 pIC50 | 19039322 |
| tyrosine kinase non receptor 2 TNK2 |
Inhibition | 8.569999694824219 pIC50 | 19039322 |
SOURCE
NLM RxNorm
5 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| BOSUTINIB | 1307619 | SU | MTHSPL |
| BOSUTINIB MONOHYDRATE | 1314319 | SU | MTHSPL |
| bosutinib | 1307619 | IN | RXNORM |
| Bosulif | 1307625 | BN | RXNORM |
| bosutinib monohydrate | 1314319 | PIN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abdominal discomfort | bosutinib | LLT | C0232487 |
| Abdominal discomfort | bosutinib | PT | C0232487 |
| Abdominal pain | bosutinib | LLT | C0000737 |
| Abdominal pain | bosutinib | PT | C0000737 |
| Abdominal pain lower | bosutinib | LLT | C0232495 |
| Abdominal pain lower | bosutinib | PT | C0232495 |
| Abdominal pain upper | bosutinib | LLT | C0232492 |
| Abdominal pain upper | bosutinib | PT | C0232492 |
| Abdominal tenderness | bosutinib | LLT | C0232498 |
| Abdominal tenderness | bosutinib | PT | C0232498 |
| Acne | bosutinib | LLT | C0702166 |
| Acne | bosutinib | PT | C0702166 |
| Acute lymphocytic leukaemia | bosutinib | LLT | C0023449 |
| Acute lymphocytic leukaemia | bosutinib | PT | C0023449 |
| Acute pulmonary oedema | bosutinib | LLT | C0155919 |
| Acute pulmonary oedema | bosutinib | PT | C0155919 |
| Agranulocytosis | bosutinib | LLT | C0001824 |
| Agranulocytosis | bosutinib | PT | C0001824 |
| Alanine aminotransferase increased | bosutinib | LLT | C0151905 |
| Alanine aminotransferase increased | bosutinib | PT | C0151905 |
| Amylase increased | bosutinib | PT | C0151479 |
| Anaemia | bosutinib | LLT | C0002871 |
| Anaemia | bosutinib | PT | C0002871 |
| Anaphylactic shock | bosutinib | LLT | C0002792 |
| Anaphylactic shock | bosutinib | PT | C0002792 |
| Arthralgia | bosutinib | LLT | C0003862 |
| Arthralgia | bosutinib | PT | C0003862 |
| Aspartate aminotransferase increased | bosutinib | LLT | C0151904 |
| Aspartate aminotransferase increased | bosutinib | PT | C0151904 |
| Asthenia | bosutinib | LLT | C0004093 |
| Asthenia | bosutinib | PT | C0004093 |
| Asthenia | bosutinib | PT | C0004093 |
| Atypical pneumonia | bosutinib | LLT | C1412002 |
| Atypical pneumonia | bosutinib | PT | C1412002 |
| Back pain | bosutinib | LLT | C0004604 |
| Back pain | bosutinib | PT | C0004604 |
| Blood amylase increased | bosutinib | LLT | C0852913 |
| Blood and lymphatic system disorders | bosutinib | - | C0851353 |
| Blood bilirubin increased | bosutinib | LLT | C0311468 |
| Blood bilirubin increased | bosutinib | PT | C0311468 |
| Blood creatine phosphokinase increased | bosutinib | LLT | C0853034 |
| Blood creatine phosphokinase increased | bosutinib | PT | C0853034 |
| Blood creatinine increased | bosutinib | LLT | C0235431 |
| Blood creatinine increased | bosutinib | PT | C0235431 |
| Body temperature increased | bosutinib | LLT | C0015967 |
| Body temperature increased | bosutinib | PT | C0015967 |
| Bronchitis | bosutinib | LLT | C0006277 |
| Bronchitis | bosutinib | PT | C0006277 |
| Bronchopneumonia | bosutinib | LLT | C0006285 |
| Bronchopneumonia | bosutinib | PT | C0006285 |
| Cardiac disorder | bosutinib | LLT | C0018799 |
| Cardiac disorder | bosutinib | PT | C0018799 |
| Chest discomfort | bosutinib | LLT | C0235710 |
| Chest discomfort | bosutinib | PT | C0235710 |
| Chest pain | bosutinib | LLT | C0008031 |
| Chest pain | bosutinib | PT | C0008031 |
| Chest pain | bosutinib | PT | C0008031 |
| Connective tissue disorder | bosutinib | LLT | C0009782 |
| Connective tissue disorder | bosutinib | PT | C0009782 |
| Cough | bosutinib | LLT | C0010200 |
| Cough | bosutinib | PT | C0010200 |
| Cytolytic hepatitis | bosutinib | LLT | C0919823 |
| Decreased appetite | bosutinib | LLT | C0232462 |
| Decreased appetite | bosutinib | PT | C0232462 |
| Dehydration | bosutinib | LLT | C0011175 |
| Dehydration | bosutinib | PT | C0011175 |
| Dermatitis | bosutinib | PT | C0011603 |
| Diarrhoea | bosutinib | LLT | C0011991 |
| Diarrhoea | bosutinib | PT | C0011991 |
| Discomfort | bosutinib | PT | C0234215 |
| Dizziness | bosutinib | LLT | C0012833 |
| Dizziness | bosutinib | PT | C0012833 |
| Drug eruption | bosutinib | LLT | C0011609 |
| Drug eruption | bosutinib | PT | C0011609 |
| Drug hypersensitivity | bosutinib | LLT | C0013182 |
| Drug hypersensitivity | bosutinib | PT | C0013182 |
| Dysgeusia | bosutinib | LLT | C0013378 |
| Dysgeusia | bosutinib | PT | C0013378 |
| Dyspnoea | bosutinib | LLT | C0013404 |
| Dyspnoea | bosutinib | PT | C0013404 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Bosutinib used for in pharmaceutical contexts?
Bosutinib (CAS 380843-75-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Bosutinib?
Bosutinib has 877 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Diarrhoea, Neoplasm progression, Pleural effusion, Cytogenetic analysis abnormal, Nausea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Bosutinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Bosutinib.
What clinical phase is Bosutinib in?
No phase 1-4 clinical development badge is rendered for Bosutinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Bosutinib?
Bosutinib has 204 bioactivity rows in this page query. Rendered target entries include Tyrosine-protein kinase JAK3, Macrophage-stimulating protein receptor, ATP-binding cassette sub-family G member 2, Platelet-derived growth factor receptor beta, Tyrosine-protein kinase ABL1.